Hillevax Inc (HLVX) - Total Liabilities
Based on the latest financial reports, Hillevax Inc (HLVX) has total liabilities worth $27.09 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hillevax Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Hillevax Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Hillevax Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Hillevax Inc asset portfolio.
Hillevax Inc Competitors by Total Liabilities
The table below lists competitors of Hillevax Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Harrisons Holdings (Malaysia)
KLSE:5008
|
Malaysia | RM494.98 Million |
|
Purit Co. Ltd.
KQ:445180
|
Korea | ₩18.83 Billion |
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩50.75 Billion |
|
Dyaco International Inc
TW:1598
|
Taiwan | NT$5.20 Billion |
|
Averlogic Technologies
TWO:6198
|
Taiwan | NT$1.45 Billion |
|
TONGDAO LIEP.GR. DL-0001
F:6WT
|
Germany | €1.28 Billion |
|
HELIOS FAIRFAX PARTNERS
F:3UD
|
Germany | €95.85 Million |
|
Horizon Minerals Ltd
AU:HRZ
|
Australia | AU$110.94 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Hillevax Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hillevax Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hillevax Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hillevax Inc (2019–2024)
The table below shows the annual total liabilities of Hillevax Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $38.20 Million | -51.58% |
| 2023-12-31 | $78.91 Million | +57.87% |
| 2022-12-31 | $49.98 Million | -78.07% |
| 2021-12-31 | $227.92 Million | +6852.90% |
| 2020-12-31 | $3.28 Million | +192.16% |
| 2019-12-31 | $1.12 Million | -- |
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more